Corcept Therapeutics
Develops cortisol-modulating medicines for endocrine disease and cancer.
Something off on this page? Send us feedback.
Profile
Sells Korlym for endogenous Cushing's syndrome and Lifyorli, an ovarian-cancer therapy used with nab-paclitaxel. The commercial-stage business is built around cortisol modulation, with Korlym its commercial base and Lifyorli extending the platform into oncology.
Markets Korlym for endogenous Cushing's syndrome and an authorized generic, while Lifyorli is approved with nab-paclitaxel for specified platinum-resistant ovarian, fallopian-tube, and primary-peritoneal cancers.
The commercial-stage business centers on cortisol modulation, with additional clinical work in Cushing's syndrome, solid tumors, ALS, and liver disease. Korlym is marketed in the United States and remains the commercial base; Lifyorli extends the platform into oncology.
Generic mifepristone competition, Korlym patent litigation, and distinct FDA paths for relacorilant shape the business. Its hypercortisolism application received a Complete Response Letter, separate from Lifyorli's oncology approval.
Company facts
Key statistics
Year to date +198% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Truist Financial | Target | $50 | $164 | ||
| Jul 30, 2026 | H.C. Wainwright | Reiterate | Buy | $95 | $165 | |
| Jul 29, 2026 | Canaccord Genuity | Reiterate | Buy | $100 | $150 | |
| Jul 27, 2026 | Wolfe Research | Downgrade | Peer Perform | Underperform | $30 | $50 |
| Jun 2, 2026 | H.C. Wainwright | Target | $75 | $95 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $0.02 | $0.36 | +1,383.3% | $221.1M | $256.1M | +15.8% | +27.29% |
| Apr 30, 2026Q1 FY26 | −$0.14 | −$0.30 | −111.3% | $185.3M | $164.9M | −11.0% | +10.53% |
| Feb 24, 2026Q4 FY25 | $0.33 | $0.20 | −39.4% | $254.9M | $202.1M | −20.7% | −0.71% |
| Nov 4, 2025Q3 FY25 | $0.18 | $0.16 | −11.1% | $255.3M | $207.6M | −18.7% | +7.81% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $157.2M | $194.4M | $207.6M | $202.1M | $164.9M | $256.1M | |
| Gross profit | $154.8M | $191.0M | $203.0M | $199.6M | $162.0M | $252.1M | |
| Operating income | $3.4M | $26.7M | $10.2M | $4.5M | −$49.6M | $41.3M | |
| Net income | $20.5M | $35.1M | $19.7M | $24.3M | −$31.2M | $42.1M | |
| Diluted EPS | $0.17 | $0.29 | $0.16 | $0.20 | −$0.30 | $0.36 | |
| Gross margin | 98.5% | 98.2% | 97.8% | 98.7% | 98.3% | 98.4% | |
| Operating margin | 2.2% | 13.7% | 4.9% | 2.2% | -30.1% | 16.1% |
Fiscal years (4-quarter sums)FY21 $366.0M · FY22 $401.9M · FY23 $482.4M · FY24 $675.0M · FY25 $761.4M
Balance sheet, Jun 30, 2026Cash & short-term investments $308.2M · Total debt $9.4M · Total assets $888.7M · Shareholders' equity $705.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 108.10M · Float 90.57M · 83.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.43M | 11.50% | 13F | Aug 7, 2026 |
| Ingalls & Snyder LLC | 7.93M | 7.34% | 13F | Aug 14, 2026 |
| Renaissance Technologies LLC | 5.26M | 4.87% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.04M | 4.67% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.17M | 3.86% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Kimberly Park | director | −26,685 | $122.55 |
| Aug 25, 2026 | Sean Maduck | officer: See Remarks | −30,955 | $125.58 |
| Aug 18, 2026 | David L. Mahoney | director | −103,606 | $118.25 |
| Aug 17, 2026 | Gary Charles Robb | officer: Chief Business Officer | −10,000 | $116.26 |
| Aug 14, 2026 | James N. Wilson | director | −10,000 | $111.43 |
Peers
- Teva (ADR)
Generic mifepristone challenges Korlym in Cushing's syndrome
- Xeris Biopharma
Recorlev competes in medical treatment of hypercortisolism
- Merck
Keytruda regimen overlaps in platinum-resistant ovarian cancer
- AbbVie
Elahere overlaps in FRα-positive platinum-resistant ovarian cancer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics | $115.08 | +1.06% | $12.31B | 271.1 | 28.5 | 14.8 | +31.7% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Xeris Biopharma | $8.48 | +0.06% | $1.46B | — | 47.8 | 4.4 | +27.2% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Median | 72.0 | 17.0 | 4.9 | +7.6% |